Global melanoma drugs market set to grow to $12.4 billion by 2025

21 August 2017

The global melanoma therapeutics market is expected to reach $12.4 billion by 2025, according to a new report by Grand View Research. The increasing incidence of chronic diseases such as melanoma, skin cancer and skin allergies is an important driver of the market.

According to the US Centers for Disease Control and Prevention (CDC), over 71,943 people were affected by melanoma in 2013. The American Cancer Society estimates that this number will go up to 87,100 in 2017, thus highlighting the need for melanoma drugs over the forecast period.

The increasing number of Food and Drug Administration approvals and introduction of novel therapeutics with enhanced efficacy are also anticipated to present growth opportunities. Within a period of six years, ie, from 2011 to 2016, around eight biologics have been approved for the treatment of this disease, which include:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK